This study builds on the initial success of unmodified NK cells against ovarian cancer in vivo [30,31,44] and highlights the utility in modifying NK cells to specifically target receptors expressed on ovarian cancer cells surface such as TRAIL. Here, TNFSF10 is linked to ovarian carcinoma.